Individual risk stratification of gastric cancer: Evolving concepts and their impact on clinical practice

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 6, 2014, Pages 1043-1053

  Rugge, Massimo ^a   Capelle, Lisette G ^b   Fassan, Matteo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Gastric cancer; Gastritis; Gastritis staging; Molecular pathology; OLGA; OLGIM

Indexed keywords

MICRORNA; MOLECULAR MARKER; BIOLOGICAL MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; DISEASE ASSOCIATION; ENDOSCOPY; GASTRIC METAPLASIA; GASTRITIS; GENE MUTATION; HISTOLOGY; HUMAN; INTESTINE METAPLASIA; INTRAEPITHELIA NEOPLASIA; METAPLASIA; PRECANCER; PSEUDOPYLORIC METAPLASIA; RISK ASSESSMENT; SECONDARY PREVENTION; SEROLOGY; STOMACH CANCER; STOMACH CARCINOGENESIS; ADENOCARCINOMA; HELICOBACTER INFECTION; METABOLISM; MICROBIOLOGY; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; BIOMARKERS; GASTRITIS; HELICOBACTER INFECTIONS; HUMANS; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 84927964184     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.09.002     Document Type: Review

References (74)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118: 3030-44.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64: 9-29.
3. Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther 2014;14: 947-54.
4. Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, et al. A clinical-biological risk stratification model for resected gastric cancer: Prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2013;24: 693-701.
5. Yamamoto H,Watanabe Y, Maehata T, Morita R, Yoshida Y, Oikawa R, et al. An updated review of gastric cancer in the nextgeneration sequencing era: Insights from bench to bedside and vice versa. World J Gastroenterol 2014;20: 3927-37.
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513: 202-9.
7. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46: 573-82.
8. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014;46: 583-7.
9. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344: 1904-9.
10. Pizzi M, Saraggi D, Fassan M, Megraud F, Di Mario F, Rugge M. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis 2014;32: 265-74.
11. Rugge M, Fassan M, Graham DY. Clinical guidelines: Secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol 2012;9: 128-9.
12. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: From biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013;27: 205-23.
13. Correa P. Gastric cancer: Overview. Gastroenterol Clin N Am 2013;42: 211-7.
14. Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: The histology report. Dig Liver Dis - Off J Italian Soc Gastroenterol Italian Assoc Study Liver 2011;43(Suppl. 4): S373-84.
15. Fassan M, Pizzi M, Farinati F, Nitti D, Zagonel V, Genta RM, et al. Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. Am J Clin Pathol 2012;137: 727-32.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated sydney system. International Workshop on the Histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20: 1161-81.
17. Price AB. The Sydney system: Histological division. J Gastroenterol Hepatol 1991;6: 209-22.
18. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44: 74-94.
19. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005;36: 228-33.
20. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71: 1150-8.
21. Rugge M, Genta RM, Group O. Staging gastritis: An international proposal. Gastroenterology 2005;129: 1807-8.
22. Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31: 1104-11.
23. Daugule I, Sudraba A, Chiu HM, Funka K, Ivanauskas A, Janciauskas D, et al. Gastric plasma biomarkers and operative link for gastritis assessment gastritis stage. Eur J Gastroenterol Hepatol 2011;23: 302-7.
24. Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17: 4596-601.
25. den Hoed CM, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013;45: 249-56.
26. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infectionethe maastricht IV/Florence consensus report. Gut 2012;61: 646-64.
27. Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, et al. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology 2004;127: 582-94.
28. Tsai YC, Hsiao WH, Yang HB, Cheng HC, Chang WL, Lu CC, et al. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther 2013;37: 969-78.
29. Hoffmann W. Stem cells, self-renewal and cancer of the gastric epithelium. Curr Med Chem 2012;19: 5975-83.
30. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008;134: 511-22.
31. Nam KT, O'Neal RL, Coffey RJ, Finke PE, Barker N, Goldenring JR. Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut 2012;61: 1678-85.
32. Uehara T, Ma D, Yao Y, Lynch JP, Morales K, Ziober A, et al. H. pylori infection is associated with DNA damage of Lgr5-positive epithelial stem cells in the stomach of patients with gastric cancer. Dig Dis Sci 2013;58: 140-9.
33. Oshima H, Oshima M. Mouse models of gastric tumors: Wnt activation and PGE2 induction. Pathol Int 2010;60: 599-607.
34. Halldorsdottir AM, Sigurdardottrir M, Jonasson JG, Oddsdottir M, Magnusson J, Lee JR, et al. Spasmolytic polypeptideexpressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 2003;48: 431-41.
35. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95: 1431-8.
36. Babu SD, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer 2006;5: 10.
37. Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T, et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: Inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol 2004;130: 135-45.
38. Kim HS, Lee JS, Freund JN, Min KW, KimW, Juhng SW, et al. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol 2006;21: 438-42.
39. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000;92: 1881-8.
40. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54: 1536-40.
41. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: A meta-analysis. Digestion 2011;83: 253-60.
42. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: A systematic review and meta-analysis. Helicobacter 2007;12(Suppl. 2): 32-8.
43. Agreus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47: 136-47.
44. di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis - Off J Italian Soc Gastroenterol Italian Assoc Study Liver 2008;40: 523-30.
45. Leja M, Kupcinskas L, Funka K, Sudraba A, Jonaitis L, Ivanauskas A, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011;56: 145-50.
46. Correa P. Serum pepsinogens in gastric cancer screening. Dig Dis Sci 2010;55: 2123-5.
47. Gutierrez-Gonzalez L, Graham TA, Rodriguez-Justo M, Leedham SJ, Novelli MR, Gay LJ, et al. The clonal origins of dysplasia from intestinal metaplasia in the human stomach. Gastroenterology 2011;140: 1251-60. e1-6.
48. Rugge M, Leandro G, Farinati F, Di Mario F, Sonego F, Cassaro M, et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995;76: 376-82.
49. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008;134: 945-52.
50. You WC, Li JY, Blot WJ, Chang YS, Jin ML, Gail MH, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer J Int du Cancer 1999;83: 615-9.
51. Rugge M, Cassaro M, Di Mario F, Leo G, Leandro G, Russo VM, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003;52: 1111-6.
52. Rugge M, Farinati F, Baffa R, Sonego F, Di Mario F, Leandro G, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994;107: 1288-96.
53. Bornschein J, Leja M, Kupcinskas J, Link A, Weaver J, Rugge M, et al. Molecular diagnostics in gastric cancer. Front Biosci (Landmark Ed) 2014;19: 312-38.
54. Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: The molecular background. Best Pract Res Clin Gastroenterol 2013;27: 159-69.
55. Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric cancer. Dig Dis 2010;28: 609-14.
56. Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract.World J Gastroenterol 2011;17: 5231-9.
57. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer 2014;17: 442-9.
58. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43: 1219-23.
59. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44: 570-4.
60. Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer. Cancer Res 2009;69: 8223-30.
61. Dong B, Xie YQ, Chen K, Wang T, Tang W, You WC, et al. Differences in biological features of gastric dysplasia, indefinite dysplasia, reactive hyperplasia and discriminant analysis of these lesions. World J Gastroenterol 2005;11: 3595-600.
62. Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics 2012;4: 279-94.
63. Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol 2009;40: 1534-42.
64. Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu QM, et al. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 2012;118: 5507-17.
65. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int 2010;60: 337-50.
66. Compare D, Rocco A, Liguori E, D'Armiento FP, Persico G, Masone S, et al. Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol 2011;64: 677-82.
67. Zheng Z, Andersson AF, Ye W, Nyren O, Normark S, Engstrand L. A method for metagenomics of Helicobacter pylori from archived formalin-fixed gastric biopsies permitting longitudinal studies of carcinogenic risk. PLoS One 2011;6: E26442.
68. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 2010;11: 136-46.
69. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M, et al. MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int J cancer J Int du cancer 2011;128: 361-70.
70. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbetadependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008;13: 272-86.
71. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect. Int J Cancer J Int Du Cancer 2009;124: 2367-74.
72. Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 2011;56: 2009-16.
73. Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer J Int Du Cancer 2011;129: 2600-10.
74. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105: 10513-8.